Senseonics Eversense E3 Ascensia Diabetes Care
The Eversense E3 system. [Image from Ascensia/Senseonics]

Senseonics (NYSE:SENS) posted first-quarter results that topped the consensus revenue forecast on Wall Street.

The Germantown, Maryland-based company posted profits of $86.7 million, or 19¢ per share, on sales of $2.5 million for the three months ended March 31, 2022, for a massive bottom-line gain from losses of $249.5 million this time last year despite a sales decline of 12.8%.

Adjusted to exclude one-time items, losses per share were 3¢, falling level with projections on Wall Street, where analysts were looking for sales of $2.2 million.

Get the full story at our sister site, Drug Delivery Business News.